LogicBio Therapeutics (LOGC) Raised to “Hold” at Zacks Investment Research

LogicBio Therapeutics (NASDAQ:LOGC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “

Other equities analysts have also issued research reports about the stock. Chardan Capital started coverage on shares of LogicBio Therapeutics in a research report on Tuesday, November 13th. They set a “buy” rating and a $20.00 price objective for the company. ValuEngine lowered shares of LogicBio Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 26th. William Blair started coverage on shares of LogicBio Therapeutics in a research report on Tuesday, November 13th. They set an “outperform” rating and a $26.00 price objective for the company. Finally, Barclays started coverage on shares of LogicBio Therapeutics in a research report on Tuesday, November 13th. They set an “overweight” rating and a $24.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. LogicBio Therapeutics has a consensus rating of “Buy” and a consensus price target of $23.33.

LOGC opened at $9.38 on Thursday. LogicBio Therapeutics has a fifty-two week low of $6.70 and a fifty-two week high of $18.00.

LogicBio Therapeutics (NASDAQ:LOGC) last released its quarterly earnings data on Monday, December 3rd. The company reported ($4.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($3.69). Research analysts expect that LogicBio Therapeutics will post -3.16 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new position in LogicBio Therapeutics during the fourth quarter valued at $31,000. American International Group Inc. bought a new stake in shares of LogicBio Therapeutics in the 4th quarter worth about $56,000. Dean Capital Investments Management LLC bought a new stake in shares of LogicBio Therapeutics in the 4th quarter worth about $543,000. Geode Capital Management LLC bought a new stake in shares of LogicBio Therapeutics in the 4th quarter worth about $626,000. Finally, Northern Trust Corp bought a new stake in shares of LogicBio Therapeutics in the 4th quarter worth about $873,000. Institutional investors and hedge funds own 0.02% of the company’s stock.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.

Further Reading: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on LogicBio Therapeutics (LOGC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply